KR101788299B1 - Composition containing protocatechuic acid for improving pregnancy - Google Patents
Composition containing protocatechuic acid for improving pregnancy Download PDFInfo
- Publication number
- KR101788299B1 KR101788299B1 KR1020160012900A KR20160012900A KR101788299B1 KR 101788299 B1 KR101788299 B1 KR 101788299B1 KR 1020160012900 A KR1020160012900 A KR 1020160012900A KR 20160012900 A KR20160012900 A KR 20160012900A KR 101788299 B1 KR101788299 B1 KR 101788299B1
- Authority
- KR
- South Korea
- Prior art keywords
- female infertility
- protocatechuic acid
- infertility
- originating
- origin
- Prior art date
Links
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 title claims abstract description 128
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 230000035935 pregnancy Effects 0.000 title abstract description 23
- 108090000581 Leukemia inhibitory factor Proteins 0.000 claims abstract description 35
- 239000004480 active ingredient Substances 0.000 claims abstract description 21
- 208000000509 infertility Diseases 0.000 claims abstract description 18
- 231100000535 infertility Toxicity 0.000 claims abstract description 18
- 230000036512 infertility Effects 0.000 claims abstract description 18
- 210000005168 endometrial cell Anatomy 0.000 claims abstract description 12
- 230000001965 increasing effect Effects 0.000 claims abstract description 11
- 230000002265 prevention Effects 0.000 claims abstract description 10
- 230000001605 fetal effect Effects 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims abstract description 3
- 102000004058 Leukemia inhibitory factor Human genes 0.000 claims description 34
- 210000004027 cell Anatomy 0.000 claims description 34
- 206010021928 Infertility female Diseases 0.000 claims description 32
- 208000007984 Female Infertility Diseases 0.000 claims description 29
- 235000013305 food Nutrition 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 210000004291 uterus Anatomy 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 7
- 108010000912 Egg Proteins Proteins 0.000 claims description 7
- 210000004681 ovum Anatomy 0.000 claims description 7
- 201000005670 Anovulation Diseases 0.000 claims description 6
- 206010002659 Anovulatory cycle Diseases 0.000 claims description 6
- 206010010356 Congenital anomaly Diseases 0.000 claims description 6
- 231100000552 anovulation Toxicity 0.000 claims description 6
- 210000003101 oviduct Anatomy 0.000 claims description 5
- 208000031481 Pathologic Constriction Diseases 0.000 claims description 3
- 239000012528 membrane Substances 0.000 claims description 3
- 230000036262 stenosis Effects 0.000 claims description 3
- 208000037804 stenosis Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 210000003754 fetus Anatomy 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000003092 female infertility of uterine origin Diseases 0.000 claims 2
- 238000002513 implantation Methods 0.000 abstract description 16
- 230000001737 promoting effect Effects 0.000 abstract description 15
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 7
- 230000001939 inductive effect Effects 0.000 abstract description 4
- 210000002993 trophoblast Anatomy 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 2
- 235000013376 functional food Nutrition 0.000 abstract description 2
- 230000001364 causal effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 8
- 210000004696 endometrium Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000004720 fertilization Effects 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- -1 liquid paraffin Polymers 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102000003815 Interleukin-11 Human genes 0.000 description 2
- 108090000177 Interleukin-11 Proteins 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 206010000210 abortion Diseases 0.000 description 2
- 231100000176 abortion Toxicity 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 230000032692 embryo implantation Effects 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000008175 fetal development Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940074383 interleukin-11 Drugs 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 239000011787 zinc oxide Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241001478740 Lilium sp. Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- RINSJDWDXSWUOK-UHFFFAOYSA-N OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 Chemical compound OC(=O)C1=CC=C(O)C(O)=C1.OC(=O)C1=CC=C(O)C(O)=C1 RINSJDWDXSWUOK-UHFFFAOYSA-N 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000011707 Ovulation disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000001047 purple dye Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RMNIZOOYFMNEJJ-UHFFFAOYSA-K tripotassium;phosphate;hydrate Chemical compound O.[K+].[K+].[K+].[O-]P([O-])([O-])=O RMNIZOOYFMNEJJ-UHFFFAOYSA-K 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention provides a composition for promoting pregnancy or a composition for the prevention or treatment of gynecological infertility comprising protocatechuic acid as an active ingredient. The protocatechuic acid of the present invention increases the expression of LIF associated with the implantation in the endometrial cells and has an excellent effect of effectively inducing the implantation of the embryo by increasing the binding force between the endometrial cells and the fetal-derived trophoblast, Can be useful in fields related to pharmaceuticals and functional foods that can prevent and treat gynecological infertility including causal infertility.
Description
The present invention provides a composition for promoting pregnancy or a composition for the prevention or treatment of gynecological infertility comprising protocatechuic acid as an active ingredient.
In recent years, in conjunction with an aging society, infertility is increasing as maternal age increases. In addition, due to environmental pollution caused by industrialization and the advancement of women into society, the stress of women is increasing, and the pregnancy rate is significantly lowered. Common causes of female infertility include ovulation disorders, transfer of fertilized eggs, and implantation disorders. Infertility due to obstructive ovarian failure and transfer of embryos is largely solved through in vitro fertilization (IVF), but sterilization due to implantation disorder has yet to be clarified. Normal pregnancy progresses in the order of fertilization, implantation and fetal development. Quality of fertilized eggs and receptivity of endometrium are very important factors in embryo implantation. The major factors controlling the endometrium's water solubility include growth factors such as cytokine such as leukemia inhibitory factor (LIF), insulin-like growth factor-2 and interleukin-11 (IL-11) is important (Hum Rep Update, 12 (6): 731-746). Among them, the expression of LIF, an interleukin-6 (IL-6) family cytokine, is known to be a key factor controlling the implantation process. In particular, in mice deficient in LIF, there are reports of defects in the adhesion process between the embryo and the endometrium and conception and pregnancy (Nature 359 (6390): 76-79; Endocrinology 150 6): 2915-2923). In addition, it has been reported that inhibition of LIF function by using an antagonist for LIF does not result in implantation (PNAS 104 (49): 19357-19362). LIF is known to be the most important factor in the implantation process have.
Protocatechuic acid (Protocatechuic acid) is the first isolate from Magnolia and Lilium sp., And is also present in Magnolia and other plants. Protocatechuic acid has been reported to ameliorate neuropsychiatric dysfunction induced by chronic intermittent hypoxia (Sci. Rep. 5: 14507) and to protect the brain's mitochondrial function in diabetic rat models (Appl Physiol Nutr Metab. 40 10): 1078-81). There is also a report that protocatechuic acid inhibits oxidized LDL-induced apoptosis in macrophages (Oxid Med Cell Longev. 2015: 351827) and is effective in antiinflammatory and neuroprotective actions (Neurochem Res 40 (8): 1655-60, Free Radic Biol Med. 84: 331-43). However, there has been no previous report that protocatechuic acid is effective for the prevention or treatment of infertility and for pregnancy.
The present inventors have found that protocatechuic acid increases the expression of LIF, a key cytokine related to the implantation in endometrial cells, in inducing fertilization of embryos and effective in promoting pregnancy. Thus, the endometrial cells and embryo- The present invention has been accomplished by confirming that the present invention is effective in promoting pregnancy and promoting ovarian non-implantation in female infertility by increasing cell binding.
It is an object of the present invention to provide a composition for promoting pregnancy comprising protocatechuic acid as an active ingredient.
It is also an object of the present invention to provide a composition for the prevention or treatment of gynecological infertility comprising protocatechuic acid as an active ingredient.
In order to solve the above problems, the present invention provides a pharmaceutical composition for promoting pregnancy comprising protocatechuic acid as an active ingredient.
In addition, the present invention provides a food composition for promoting pregnancy comprising protocatechuic acid as an active ingredient.
The present invention also provides a pharmaceutical composition for the prevention or treatment of gynecological infertility comprising protocatechuic acid as an active ingredient.
The present invention also provides a food composition for preventing or ameliorating gynecological infertility comprising protocatechuic acid as an active ingredient.
The protocatechuic acid of the present invention has an excellent effect of increasing the expression of LIF related to the implantation in the endometrial cells, increasing the binding force between the endometrial cells and the fetal-derived trophoblast and effectively inducing the implantation of the embryo. Accordingly, the protocatechuic acid according to the present invention can be usefully used in fields related to medicines and functional foods for prevention and treatment of gynecological infertility including oocyte non-implantation infertility.
Figure 1 shows the formula of protocatechuic acid.
FIG. 2 is a graph showing the results of confirming cytotoxicity according to the concentration of protocatechuic acid treatment. FIG.
FIG. 3 is a graph showing the results of RT-PCR for the increase in the expression of LIF mRNA according to the concentration of protocatechuic acid treatment.
FIG. 4 is a graph showing the result of Western blot analysis of the increase in the expression of LIF protein according to the treatment concentration of protocatechuic acid.
Fig. 5 is a graph showing the results (A) and (B) of counting the adhesion of the spermatids by fluorescent microscopy in Ishikawa cells treated with protocatechuic acid and in the untreated control group.
The present invention provides a composition for promoting pregnancy comprising protocatechuic acid as an active ingredient.
In the present invention, the term " protocatechuic acid "is a polyphenolic compound, which has been reported to have excellent antioxidative and antiinflammatory properties. Is a material having the formula C 7 H 6 O 4 and a molecular weight of 154, which is shown in FIG. 1 of the present invention.
The protocatechuic acid increases, but is not limited to, the expression of leukemia inhibitory factor (LIF).
The protocatechuic acid can be treated at a concentration of 1 to 600 μM, but preferably at a concentration of 30 to 60 μM. When protocatechuic acid is within the above-mentioned range, it is more preferable because it has no cytotoxicity.
In the present invention, "pregnancy" is a process in which the fertilized egg is implanted in the inner wall of the uterus, is supplied with nutrition from the mother, and develops into the fetus. The normal pregnancy process proceeds in the order of fertilization, implantation and fetal development.
The term "fertilization" means that an ovum ovulated in a female ovary meets with spermatozoa at the upper part of the oviduct to form an embryo. The ovum has the ability to stay alive for 1-2 days after ovulation and the sperm to remain alive for 2-3 days in the uterus, and the sperm survive for one week after being ejaculated. Sperm are spermatozoa that reach the ovary close to the
The "implantation" refers to a phenomenon in which an embryo in which a sperm and an egg are brought together at the upper part of the oviduct is moved to the uterus repeatedly and buried in the uterine wall in a bladder state. After the embryo is conceived, it is called pregnancy. Embryos implanted into the uterus are born after about nine months of age, while being fed from the uterine lining.
The composition comprises a pharmaceutical composition or a food composition.
The composition may contain protocatechuic acid alone, or may further contain a substance effective for promoting pregnancy as an active ingredient. In addition to the active ingredient, the composition may contain additional ingredients, Acceptable or nutritionally acceptable carrier, excipient, diluent or subcomponent.
More specifically, the pharmaceutical composition for promoting pregnancy comprising the above-mentioned protocatechuic acid may further contain, in addition to the above-mentioned active ingredients, a nutritional supplement, a vitamin, an electrolyte, a flavoring agent, a colorant, a thickening agent, a pectic acid and a salt thereof, , Protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, Calcium stearate, mineral oil, calcium carbonate, dextrin, propyleneglycol, liquid paraffin, sodium carboxymethylcellulose, sodium carboxymethylcellulose, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, And physiological saline, but is not limited thereto. The components may be added to the active ingredient, i.e., protocatechuic acid, either independently or in combination.
The composition according to the present invention can be used alone for promoting pregnancy, or in combination with surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
The composition according to the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) according to a desired method, and the dosage may be appropriately selected according to the weight, age, sex, The range varies depending on the condition, diet, time of administration, method of administration, excretion rate and severity of the disease. The daily dose of protocatechuic acid of the present invention is 0.01 to 10000 mg / kg, preferably 1 to 20 mg / kg, and is preferably administered once to three times a day.
According to one embodiment of the present invention, the protocatechuic acid increases the expression of leukemia inhibitory factor (LIF), thereby increasing the binding force between endometrial cells and fetal-derived trophoblast cells and effectively inducing embryo implantation .
In addition, the present invention provides a food composition for promoting pregnancy comprising protocatechuic acid as an active ingredient.
The composition according to the present invention may be included in a health food for the purpose of promoting pregnancy. When the active ingredient of the present invention is used as a food additive, the composition isolated from the synthesis or the extract may be added as it is, And can be suitably used according to a conventional method. The amount of the active ingredient to be mixed may be appropriately adjusted depending on the intended use (prevention, health or therapeutic treatment).
There is no particular limitation on the kind of the food. Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, drinks, tea, , Alcoholic beverages and vitamin complexes, and includes all health foods in a conventional sense.
Various additives such as flavors or natural carbohydrates can be used as the food-aid additive of the present invention. The above-mentioned natural carbohydrates are sugar saccharides such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like.
In addition to the above, the composition according to the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid concentrating agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. In addition, the composition according to the present invention may contain flesh for the production of natural fruit juice, fruit juice beverage and vegetable beverage. These components may be used independently or in combination.
The present invention also provides a composition for preventing or treating feminine infertility comprising protocatechuic acid as an active ingredient.
The composition comprises a pharmaceutical composition or a food composition.
The female infertility is related to nonimplantation of ovum, female infertility associated with anovulation associated with anovulation, female infertility of tubal origin, Tubal occlusion, Tubal stenosis, Female infertility of the uterine origin, Infertility of the uterus, Infertility of the uterus, Infertility associated with male factors, female infertility associated with cervical origins, female infertility associated with male factors, and other factors related to congenital anomaly of uterus. At least one selected from the group consisting of female infertility of other origin and unspecified female infertility (unspecified) However, not limited to this.
In the present invention, the above-mentioned "Nonimplantation of ovum" is a representative cause of female infertility. During fertilization, the embryo moves while dividing cells into the uterus, and when it reaches the blastocyst stage, it is buried in the endometrium and seated. However, when embryos are not thick enough to be implanted or stiff due to damage, it is difficult to obtain implants, and abortion is often caused by lack of space due to adhesion of the uterine wall. Endometrial hyperplasia due to intrauterine inflammation caused by spontaneous abortion, mastectomy, abortion, endometritis, pelvic tuberculosis and intrauterine device, or uterine myopathy, Or if the uterine endometrium is incomplete due to congenital abnormal uterine hormone secretion. The oocyte implantation has been identified as the major cause of artificial insemination and failure of in vitro procedures.
Since the pharmaceutical composition or the food composition includes the pharmaceutical preparation or the food preparation containing the above-mentioned protocatechuic acid as an active ingredient, the contents overlapping with the composition of the present invention described above can be used in the present specification The description thereof is omitted in order to avoid excessive complexity.
It will be apparent to those skilled in the art that various modifications and variations can be made in the present invention without departing from the spirit or scope of the invention as defined by the appended claims. It will be obvious to you.
Example One. Protocatechus Cytotoxicity Assessment
The toxicity of protocatechuic acid to cells was confirmed by MTT (3- (4,5-dimethylthiazole-2-yl) -2,5-diphenyltetrazoli-umbromide) analysis.
Specifically, protocatechuic acid having the formula of Fig. 1 was treated at the concentration of 0, 10, 30, 50, 100 and 500 μM for 24 hours in the endometrial cell line Ishikawa cell. The MTT solution (2 mg / ml) was reacted at 37 ° C for 4 hours in a CO 2 incubator and the supernatant was removed. Live cells were reduced by intracellular redox enzyme, and purple dyes (Formazan) were dissolved in DMSO and measured at 540 nm wavelength with a microplate reader. Live cells were expressed as percentage compared to the control group. The results are shown in Fig.
As shown in FIG. 2, it was confirmed that even when the protocatechuic acid was treated to a concentration of 500 μM, no significant cytotoxicity was confirmed. Therefore, the concentrations below 50 μM without toxicity were used in the experiments below.
Example 2. Protocatechus Leukemia inhibitory factor (leukemia inhibitory factor; LIF ) mRNA Confirmation of expression of
The expression level of LIF mRNA according to the treatment concentration of protocatechuic acid was confirmed by RT-PCR.
Specifically, protocatechuic acid was treated with Ishikawa cells at concentrations of 0, 10, 30 and 50 μM and cultured for 24 hours. Then, the RNAs of the cells treated at the respective concentrations were extracted and primers specific for LIF were used. The sequence of the primer was 5'-GGCCCGGACACCCATAGACG-3 '(SEQ ID NO: 1) in the forward direction and 5'-CCACGCGCCATCCAGGTAAA-3' (SEQ ID NO: 2) in the reverse direction. The primer sequence used for amplification of- 3 '(SEQ ID NO: 3) and 5'-TCCTTCTGCATCCTGTCGGCA-3' (SEQ ID NO: 4) in the reverse direction. CDNA was synthesized by total RNA, oligo-dT primer and M-MLV reverse transcriptase at 42 ° C for 1 hour. The cDNA was amplified by 30 cycles of denaturation at 95 ° C. for 30 seconds, annealing at 60 ° C. for 30 seconds, and extension at 72 ° C. for 30 seconds using the primers described above. And the amount of mRNA expression was confirmed by polymerase chain reaction. The amplified DNA was electrophoretically photographed under ultraviolet light (UV) and the intensity of the band was measured using a densitometry. In addition, the ratio of the expression level of LIF mRNA and the expression level of alpha-actin mRNA as a control standard was confirmed. The results are shown in Fig.
As shown in FIG. 3, when the endometrial cells were treated with protocatechuic acid at a concentration of 50 μM, the expression of LIF mRNA was 2.05 times Respectively.
Therefore, it was confirmed that the expression of LIF mRNA was increased in a concentration-dependent manner of protocatechuic acid .
Example 3. Protocatechus Depending on treatment concentration LIF Identification of Protein Expression
The expression of LIF protein was confirmed by western blotting according to the treatment concentration of protocatechuic acid.
Specifically, protocatechuic acid was treated with Ishikawa cells at a concentration of 0, 10, 30 and 50 μM and cultured for 24 hours. Proteins were extracted from the cells and electrophoresed by SDS-PAGE. Subsequently, the separated proteins were transferred to a nitrocellulose membrane by electrophoresis and then sequentially bound to LIF-specific antibodies (SantaCruz) and secondary antibodies to which HRP (Horseradish peroxidase) had been added ECL (enhanced chemiluminescence) solution. The intensity of the band was measured using a densitometer and the ratio of the expression amount of LIF protein and the expression amount of GAPDH protein as a representative standard was confirmed. The results are shown in Fig.
As shown in FIG. 4, when 10, 30 and 50 μM of protocatechuic acid was treated in endometrium cells, LIF protein expression was increased to about 2.00, 2.71 and 3.27 times as compared with the control group, respectively.
Thus, it was confirmed that the expression of LIF protein was increased in a concentration-dependent manner in protocatechuic acid.
Example 4. Protocatechuic acid Of the JAR cells to the treated cells Attachment Confirm
The adherent ability of the fetal - derived trophoblast cell line to the Ishikawa cell line derived from endometrium treated with protocatechuic acid was confirmed.
Specifically, human endometrial cell line Ishikawa cells were cultured in a single layer to make 80% confluence, then treated with protocatechuic acid to a concentration of 50 μM, and cultured for 48 hours to obtain 100% Respectively. Subsequently, the pre-cultured fetal-derived cell line was removed from the culture dish, and the cell was stained well to be a single cell and stained with CellTracker ™ Green CMFDA (5-chloromethylfluorescein diacetate), a cell permeable green fluorescent substance . Thereafter, the cells were sprinkled on a single layer of Ishikawa cells and cultured in an incubator at 37 캜 for 30 minutes while stirring at a speed of about 60 rpm. The cultured cells were washed twice with phosphate buffered saline (PBS) to remove unattached cells, and the adhered cells were fixed with 3.7% formalin solution. When confirmed by fluorescence microscopy, the number of cells that fluoresce by CMFDA is the number of sperm cells attached to the Ishikawa cells on the floor, and the number of the sperm cells was measured (Fig. 5 (A)). Thereafter, the total number of cells counted in photographs of five or more different regions was compared with a control group not treated with protocatechuic acid, and then the average and standard deviation of the values repeated three times were determined (see (B )). The results are shown in Fig.
As shown in Figs. 5 (A) and 5 (B), it was confirmed that the adherence of autologous cells to Ishikawa cells treated with protocatechuic acid was significantly higher than that of the control group not treated with protocatechuate Respectively.
Hereinafter, the pharmaceutical composition of the present invention and the preparation example of the food composition will be described, but the present invention is not intended to be limited but is specifically described.
Formulation example 1. Preparation of pharmaceutical compositions
1-1. Sanje Produce
Protocatechuic acid 20 mg
The above components are mixed and filled in airtight bags to prepare powders.
1-2. Manufacture of tablets
Protocatechuic acid 10 mg
After mixing the above components, tablets are prepared by tableting according to the usual preparation method of tablets.
1-3. Preparation of capsules
Protocatechuic acid 10 mg
Lactose 14.8 mg
Magnesium stearate 0.2 mg
The above components are mixed according to a conventional capsule preparation method and filled in gelatin capsules to prepare capsules.
1-4. Injection preparation
Protocatechuic acid 10 mg
180 mg mannitol
Sterile sterilized water for injection 2974 mg
Na2HPO42H2O 26 mg
(2 ml) per 1 ampoule in accordance with the usual injection preparation method.
1-5. Liquid Produce
Protocatechuic acid 20 mg
10 g per isomer
5 g mannitol
Purified water quantity
Each component was added and dissolved in purified water according to the usual liquid preparation method, and the lemon flavor was added in an appropriate amount. Then, the above components were mixed, and purified water was added thereto. The whole was added with purified water to adjust the total volume to 100 ml, And sterilized to prepare a liquid preparation.
Formulation example 2. Preparation of food composition
2-1. Health food manufacturing
100 mg of protocatechuic acid, a proper amount of vitamin mixture, 70 g of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1, 0.15 mg of vitamin B2, 0.2 mg of vitamin B6, 0.2 g of vitamin B12, 10 mg of vitamin C, 1.7 mg, folate 50 g, calcium pantothenate 0.5 mg, an appropriate amount of inorganic mixture, ferrous sulfate 1.75 mg, zinc oxide 0.82 mg, magnesium carbonate 25.3 mg, potassium phosphate monohydrate 15 mg, dibasic calcium phosphate 55 mg, potassium citrate 90 mg , Calcium carbonate (100 mg) and magnesium chloride (24.8 mg), granules were prepared, and a health food was prepared according to a conventional method. At this time, although the composition ratio of the vitamin and mineral mixture is relatively mixed with the ingredient suitable for health food, it may be arbitrarily modified.
2-2. Health drink manufacturing
According to the conventional health drink manufacturing method, 100 mg of protocatechuic acid, 15 g of vitamin C, 100 g of vitamin E (powder), 19.75 g of iron lactate, 3.5 g of zinc oxide, 3.5 g of nicotinic acid amide, 0.2 g of vitamin A, 0.3 g of vitamin B2 and a predetermined amount of water were mixed and heated at 85 DEG C for about 1 hour with stirring. The resulting solution was filtered and sterilized in a 2 L container to be sterilized by sealing, and then stored in a refrigerator to prepare a health drink. At this time, although the composition ratio of the ingredients suitable for the beverage is comparatively mixed, the mixture ratio may be arbitrarily varied according to the demand, the demanded country, the intended use, and the regional or national preference.
<110> Pusan National University Industry-University Cooperation Foundation <120> Composition containing protocatechuic acid for improving pregnancy <130> 1-263 <160> 4 <170> Kopatentin 2.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> forward primer for LIF <400> 1 ggcccggaca cccatagacg 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> reverse primer for LIF <400> 2 ccacgcgcca tccaggtaaa 20 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> forward primer for alpha-actin <400> 3 caagagatgg ccacggctgc t 21 <210> 4 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> reverse primer for alpha-actin <400> 4 tccttctgca tcctgtcggc a 21
Claims (8)
Wherein said protocatechuic acid increases the expression level of a leukemia inhibitory factor (LIF) to increase adherence of endometrial cells and fetal-derived drug-derived membrane cells to a pharmaceutical composition for the prevention or treatment of gynecological infertility .
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160012900A KR101788299B1 (en) | 2016-02-02 | 2016-02-02 | Composition containing protocatechuic acid for improving pregnancy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160012900A KR101788299B1 (en) | 2016-02-02 | 2016-02-02 | Composition containing protocatechuic acid for improving pregnancy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170091954A KR20170091954A (en) | 2017-08-10 |
| KR101788299B1 true KR101788299B1 (en) | 2017-10-19 |
Family
ID=59652303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160012900A KR101788299B1 (en) | 2016-02-02 | 2016-02-02 | Composition containing protocatechuic acid for improving pregnancy |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101788299B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462946A (en) | 2013-09-18 | 2013-12-25 | 三峡大学 | New applications of protocatechuic acid in preparing medicaments |
| CN105250246A (en) | 2015-09-18 | 2016-01-20 | 华北理工大学 | Application of protocatechualdehyde in treatment of male infertility and in-vitro treatment of sperms |
-
2016
- 2016-02-02 KR KR1020160012900A patent/KR101788299B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103462946A (en) | 2013-09-18 | 2013-12-25 | 三峡大学 | New applications of protocatechuic acid in preparing medicaments |
| CN105250246A (en) | 2015-09-18 | 2016-01-20 | 华北理工大学 | Application of protocatechualdehyde in treatment of male infertility and in-vitro treatment of sperms |
Non-Patent Citations (1)
| Title |
|---|
| ZHONGGUO ZHONG YAO ZA ZHI. 2010 DEC;35(24):3362-7. |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170091954A (en) | 2017-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102376425B1 (en) | Composition useful for promoting female fertility | |
| KR101538047B1 (en) | Composition containing polysacchride-removed Paeonia lactiflora extract for improving pregnancy | |
| KR100815171B1 (en) | Cyclooxygenase Inhibitor, and Food and Beverage containg the Same | |
| KR101742968B1 (en) | Composition containing alpha-cyperone for improving pregnancy | |
| KR101697915B1 (en) | Composition containing paeoniflorin for preventing or treating infertility | |
| KR101802675B1 (en) | A herbal mixtuer extract with improved implantation and use thereof | |
| KR101787008B1 (en) | A composition comprising the combination of flavonoid derivatives and iridoid derivatives for treating and preventing Male Infertility | |
| KR101481569B1 (en) | A composition comprising an extract of combined crude drugs for treating and preventing Male Infertility | |
| KR20210020988A (en) | Composition for stimulation of bone formation comprising xanthorrhizol as effective component | |
| KR101730949B1 (en) | Compositions for preventing or treating infertility comprising an extract of Perilla frutescens | |
| KR101788299B1 (en) | Composition containing protocatechuic acid for improving pregnancy | |
| KR101683344B1 (en) | Composition comprising carnosic acid for preventing or improving menopausal symptoms | |
| KR101669887B1 (en) | Composition containing benzoic acid for improving pregnancy | |
| KR101667242B1 (en) | Composition containing paeonol for preventing or treating infertility | |
| KR101787006B1 (en) | A composition comprising iridoid derivatives for treating and preventing Male Infertility | |
| KR101897896B1 (en) | Composition comprising Coumestrol for improving pregnancy | |
| ES2940465T3 (en) | Tungsten (VI) salts to stimulate fertility and reproduction and to improve the effectiveness of assisted reproductive techniques | |
| KR101826109B1 (en) | Food composition for improvement of osteoporosis and pharmaceutical compositions for prevention or treatment of osteoporosis with gossypetin | |
| KR102658030B1 (en) | Composition for preventing, treating or improving bone disease or menopausal disease comprising demineralized glasswort extract or fractions thereof, and method for preparing the same | |
| KR102162787B1 (en) | A composition for promoting differentiation of myoblast comprising sabinene | |
| KR101879975B1 (en) | Composition comprising Naringenin for improving pregnancy | |
| KR20160040795A (en) | A composition comprising dovitinib (TKI258), a multi-kinase inhibitor, as an active ingredient for preventing or treating osteoporosis | |
| KR101774905B1 (en) | Composition for preventing or treating cancer comprising otobaphenol | |
| KR20200041568A (en) | Composition for preventing, ameliorating or treating infertility caused by implantation failure comprising ginseng extract as effective component | |
| KR101872770B1 (en) | Composition for preventing or treating cancer comprising novel selenobenzene compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right |